Functional differences between PD-1+ and PD-1- CD4+ effector T cells in healthy donors and patients with glioblastoma multiforme by Goods, Brittany A. et al.
Functional differences between
PD-1+ and PD-1- CD4+ effector T
cells in healthy donors and patients
with glioblastoma multiforme
The Harvard community has made this
article openly available.  Please share  how
this access benefits you. Your story matters
Citation Goods, Brittany A., Amanda L. Hernandez, Daniel E. Lowther, Liliana
E. Lucca, Benjamin A. Lerner, Murat Gunel, Khadir Raddassi, Vlad
Coric, David A. Hafler, and J. Christopher Love. 2017. “Functional
differences between PD-1+ and PD-1- CD4+ effector T cells in
healthy donors and patients with glioblastoma multiforme.” PLoS
ONE 12 (9): e0181538. doi:10.1371/journal.pone.0181538. http://
dx.doi.org/10.1371/journal.pone.0181538.
Published Version doi:10.1371/journal.pone.0181538
Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:34491849
Terms of Use This article was downloaded from Harvard University’s DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at http://
nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAA
RESEARCH ARTICLE
Functional differences between PD-1+ and
PD-1- CD4+ effector T cells in healthy donors
and patients with glioblastoma multiforme
Brittany A. Goods1☯, Amanda L. Hernandez2☯, Daniel E. Lowther2☯, Liliana E. Lucca2,
Benjamin A. Lerner2, Murat Gunel3,4, Khadir Raddassi2, Vlad Coric5, David A. Hafler2,6‡,
J. Christopher Love1,6‡*
1 Departments of Biological Engineering and Chemical Engineering, Koch Institute for Integrative Cancer
Research, Massachusetts Institute of Technology, Cambridge, Massachusetts, United States of America,
2 Departments of Neurology and Immunobiology, Yale School of Medicine, New Haven, Connecticut, United
States of America, 3 Department of Genetics, Yale School of Medicine, New Haven, Connecticut, United
States of America, 4 Department of Neurosurgery, Yale School of Medicine, New Haven, Connecticut, United
States of America, 5 Bristol-Myers Squibb, Wallingford, Connecticut, United States of America, 6 The Broad
Institute of MIT and Harvard, Cambridge, MA, United States of America
☯ These authors contributed equally to this work.
‡ These authors also contributed equally to this work.
* clove@mit.edu
Abstract
Immune checkpoint inhibitors targeting programmed cell death protein 1 (PD-1) have been
highly successful in the treatment of cancer. While PD-1 expression has been widely investi-
gated, its role in CD4+ effector T cells in the setting of health and cancer remains unclear,
particularly in the setting of glioblastoma multiforme (GBM), the most aggressive and com-
mon form of brain cancer. We examined the functional and molecular features of PD-
1+CD4+CD25—CD127+Foxp3—effector cells in healthy subjects and in patients with GBM.
In healthy subjects, we found that PD-1+CD4+ effector cells are dysfunctional: they do not
proliferate but can secrete large quantities of IFNγ. Strikingly, blocking antibodies against
PD-1 did not rescue proliferation. RNA-sequencing revealed features of exhaustion in PD-
1+ CD4 effectors. In the context of GBM, tumors were enriched in PD-1+ CD4+ effectors that
were similarly dysfunctional and unable to proliferate. Furthermore, we found enrichment of
PD-1+TIM-3+ CD4+ effectors in tumors, suggesting that co-blockade of PD-1 and TIM-3 in
GBM may be therapeutically beneficial. RNA-sequencing of blood and tumors from GBM
patients revealed distinct differences between CD4+ effectors from both compartments with
enrichment in multiple gene sets from tumor infiltrating PD-1—CD4+ effectors cells. Enrich-
ment of these gene sets in tumor suggests a more metabolically active cell state with signal-
ing through other co-receptors. PD-1 expression on CD4 cells identifies a dysfunctional
subset refractory to rescue with PD-1 blocking antibodies, suggesting that the influence of
immune checkpoint inhibitors may involve recovery of function in the PD-1—CD4+ T cell
compartment. Additionally, co-blockade of PD-1 and TIM-3 in GBM may be therapeutically
beneficial.
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Introduction
Glioblastoma multiforme (GBM) is the most common primary brain tumor in adults,
accounting for 82% of cases of malignant gliomas [1,2]. The current standard of care for GBM
is surgical resection of the tumor followed by chemotherapy and radiation, with an average
survival time of 15–17 months.[3] GBM tumors are challenging to treat and recur in nearly all
patients, where the 5-year survival time is 1–5% [4]. Several targeted therapies and chemother-
apeutic agents have also failed to increase survival or enhance patient outcomes in GBM [5].
Treatment of GBM is further complicated by immunosuppressive mechanisms within the
tumor microenvironment, resulting in dampening of T cell responses through immunosup-
pressive cytokine secretion and activation of immune inhibitory cascades [6,7]. Checkpoint
inhibitors, or therapeutics that relieve immunosuppression, represent a promising avenue for
treatment given their demonstrated effectiveness in many difficult to treat and advanced
tumors such as melanoma, renal cell carcinoma, and lung cancer [8–11].
One such co-inhibitory receptor for which approved blocking antibodies exist is pro-
grammed cell death protein (PD-1). PD-1 is an inhibitory co-receptor that imparts negative
feedback on effector function and it is expressed upon T cell activation and during T cell
exhaustion [12]. One of its ligands (PD-L1) is diffusely expressed on tumor cells in 88% of
patients with newly diagnosed GBM and 72% of patients with recurrent GBM making it an
appealing co-inhibitory target for immunotherapy [13]. PD-1 is often co-expressed with other
co-inhibitory receptors including the T cell immunoglobulin and mucin-domain containing-3
(TIM-3), lymphocyte-activation gene 3 (LAG3), and cytotoxic T-lymphocyte associated pro-
tein 4 (CTLA-4) [14]. The total pattern of receptor co-expression shapes overall T cell function,
and has been used as a proxy for assessing the degree of exhaustion in T cells in chronic dis-
eases such as cancer, viral infection and autoimmunity [15–17]. While CD4+ T cells are known
to infiltrate the GBM tumor microenvironment and a significant proportion express PD-1, lit-
tle is known about their influence on an immune response [18–20]. Given the fundamental
role of the PD-1/PD-L1 axis in promoting T cell dysfunction [21], it is essential to delineate
the molecular profiles of PD-1 expressing T cells in GBM to better understand their role in
pathology.
Here, we characterized the functional and molecular signatures linked to PD-1 expression
in CD4+ effector cells isolated from healthy subjects and from cells infiltrating GBM tumors.
In healthy subjects, PD-1+CD4+CD25—CD127+Foxp3—effector cells have decreased prolifer-
ative ability and a transcriptional profile characterized by increased IFNγ, IL-17, and EOMES
expression. Surprisingly, blocking PD-1 does not rescue proliferation of PD-1 expressing
CD4+ effector cells. These data suggest that PD-1 may mark dysfunctional CD4+ effector cells,
even in the peripheral blood of healthy donors. GBM tumors were enriched with PD-1+TIM-
3+CD4+ effector cells; the percentage of which correlated with tumor grade. Like those in
healthy subjects, tumor-derived PD-1+CD4+ effector cells displayed significantly less prolifera-
tion but retained the ability to produce inflammatory cytokines. Whole transcriptome analysis
of healthy subjects and GBM patients confirmed the presence of distinct PD-1+ and PD-
1—populations with enrichment for several gene transcriptional signatures suggestive of
exhaustion in the PD-1+ subset. Tumor-infiltrating PD-1—CD4+ effectors also expressed many
unique gene sets, including those related to metabolism. Our study suggests that high PD-1
expression on human CD4 effector cells identifies a population of exhausted effector cells that
are enriched in malignant cancer and serve a crucial role in the context of inflammation and
anti-tumor responses in GBM.
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Results and discussion
PD-1+ CD4+ effector cells from healthy donors have impaired
proliferative ability but retain the capacity to produce IFNγ
We first sought to characterize the function and phenotype of PD-1+ and PD-1—populations
of CD4+CD25—CD127+Foxp3—T cells (CD4 effectors) in healthy individuals to determine if
PD-1+ marks exhausted and dysfunctional phenotypes as those previously characterized in
PD-1+ Tregs [22]. We sorted CD4 effectors into PD-1+, PD-1—and total effector cell popula-
tions (S1 Fig) and compared entry into cell cycle by CFSE dilution after stimulation with
αCD3/αCD28/αCD2. PD-1—CD4 effector cell proliferation was similar to the total effector
population, while PD-1+ CD4 effectors did not enter cell cycle (Fig 1A and 1B). We confirmed
that this was independent of CD45RO expression (S2 Fig). We next determined whether PD-1
expression was associated with cytokine secretion. PD-1+, PD-1—and total CD4 effectors were
stimulated with αCD3/αCD28/αCD2 [23] for four days before re-stimulating with PMA and
ionomycin in the presence of brefeldin A. We found significantly increased expression of the
Th1-associated cytokine IFNγ in PD-1+ CD4 effectors compared to PD-1—and total CD4
effectors, but no significant increase in the Th17-associated cytokine IL-17 (Fig 1C and 1D).
Our data suggests that PD-1+ CD4 effectors cannot enter cell cycle but, paradoxically, can
secrete inflammatory cytokines.
Proliferative ability of PD-1+ CD4 effector cells from healthy subjects is
not rescued by PD-1 blockade or by addition of IL-2
It has previously been shown that blocking CD8+PD-1+ T cells isolated from healthy donors
and non-small cell lung cancer patients with PD-1 antibodies partially restores T cell prolifer-
ative function and cytokine secretion [21,24]. Thus, we determined if the function of CD4
effectors from healthy donors could be recovered upon the addition of PD-1 blocking antibod-
ies or IL-2. Here, however, the proliferative ability of PD-1+ CD4 effectors was not rescued by
PD-1 blockade or by the addition of IL-2 (Fig 2A–2C); this effect was confirmed with isotype
control. Increased proliferation was observed when blocking PD-1 antibodies were added to
the total CD4 effector cell cultures. This suggests that anti-PD1 agents may exert therapeutic
efficacy through PD-1—CD4 effectors rather than by reversing dysfunction in T cells already
expressing PD-1 or through mechanisms not related to PD-1 signaling. Increased IFNγ expres-
sion by PD-1+CD4+ T cells, coupled with an inability to recover proliferative capacity even in
the presence of PD-1 blocking antibodies, suggests that these cells are terminally differentiated
and resistant to entry into cell cycle, as has previously been described for CD8+ T cells [25].
PD-1+ CD4 effector cells from healthy donors have a unique
transcriptional profile enriched in pro-inflammatory, exhaustive, and
apoptotic signatures
We used transcriptional profiling to better understand the observed proliferative deficiency in
PD-1+ CD4 effector cells despite retained ability to produce cytokine. PD-1+ and PD-1—CD4
effectors were sorted from healthy donors and their transcriptome profiled by RNA-sequenc-
ing. High-quality replicates were included for subsequent analysis (S1 and S2 Tables). A total
of 435 genes were identified as differentially expressed between PD-1+ and PD-1—CD4 effec-
tors (S3 Table), where IFNG, CTLA-4, and LAG-3 were significantly upregulated in PD-1+
CD4 effectors (S3A Fig). Functional classification using DAVID [26] revealed unique gene
modules in PD-1+ CD4 effectors, including enrichment of activation, apoptotic, and immune
system pathways (S3B Fig). The gene module containing PD-1 (PDCD1) also included surface
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markers and co-receptors, including integrins and TNF-family members (S4 Table). Con-
versely, there were only two modules enriched in PD-1- CD4 effectors, one containing surface
markers and the other several transcription factors (S5 Table). Taken together, these data sug-
gest that in healthy donors PD-1+ CD4 effectors are distinct from their PD-1—counterparts;
they co-express many inhibitory co-receptors and unique surface receptors, and may be
apoptotic.
Next we performed gene set enrichment analysis to identify pathways that may account for
functional differences between the two cell populations (27). We found significant enrichment
(FDR< 0.05) of 83 pathways in PD1+ cells and 73 in PD-1—cells (S5 Table). Several pathways
related to extracellular matrix and adhesion, immune system signaling, and metabolism were
enriched in PD-1+ cells (Fig 3A). Examining the top 50 features scored by GSEA, we also
found molecules involved in IFNγ and IL-17 production (Fig 3B), confirming our observed
functional data. Interestingly, we did not see enrichment in PD-1 signaling or regulation of
PD-1 signaling in PD-1+ CD4 effectors. We confirmed differential protein expression of sev-
eral surface markers by flow cytometry, which highlighted changes in CXCR5, LAG-3, and
Fig 1. PD-1+ CD4 effectors demonstrate impaired proliferative ability despite competent cytokine secretion in healthy donors. CFSE
labeled CD4 effectors (CD4+CD25—CD127+) were stimulated with αCD3/αCD28/αCD2 for 4 days. Proliferation was assessed via CFSE dilution as
measured by flow cytometry. Percentage of proliferating cells is plotted (n = 9) (A) and representative plots from one experiment (B) are shown. After
4 days, cells were restimulated with PMA (50ng/ml) and Ionomycin (250ng/ml) for 4 hours in the presence of Brefeldin A (10μg/ml) and production of
IFNγ and IL-17 were measure by flow cytometry. Cytokine production from CD4 effectors displayed as summary (n = 4) (C) and in representative
plots (D). Statistical analyses were performed using paired student’s t-test.
https://doi.org/10.1371/journal.pone.0181538.g001
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CTLA-4 (S4 Fig). We also found an increase in Annexin V expression in the PD-1+ compart-
ment, which taken with our GSEA data, may suggest a sub-population of apoptotic cells. This
alongside the presence of the transcription factor EOMES and multiple co-inhibitory receptors
suggests that PD-1+ expression in CD4+ T cells identifies an exhausted population of cells [27].
Given that we did not find enrichment in cell cycle or observe proliferation of PD-1+
CD4 effectors, we wished to determine their differentiation state. Length of telomeres can
indicate previous cell divisions; telomere shortening can induce replicative senescence and
suggest impaired function [28]. We observed significantly shorter telomeres in the PD-1+ as
compared to the PD-1—population, suggesting that PD-1+ CD4 effectors are likely termi-
nally differentiated (Fig 3C). Thus, PD-1+ CD4 effectors are replicatively exhausted and
apoptotic, despite the retained ability to produce cytokines. Expression of integrins and
general immune activation gene sets suggest that PD-1 likely marks tissue-experienced and
activated T cells. Thus, PD-1-expressing T cells may serve as a cellular window into immune
and tissue, and longitudinal characterization of PD-1 expressing T cells may yield insight
into the immune state of an individual. PD-1+ CD4 effectors from healthy donors are func-
tionally distinct and our data suggests that, in addition to its role in exhaustion, expression
of PD-1 on CD4 effectors characterizes a subset of CD4+ T cells that are unable to recover
from exhaustion and dysfunction.
Glioblastoma multiforme tumors are enriched in PD-1+Tim-3+ CD4
effector cells
PD-1 is a promising target for GBM therapy because tumors express high amounts of PD-L1
and expression of PD-1 on blood-derived T cells has been correlated with poor clinical out-
come [29]. Since tumor-infiltrating CD4+ T cells can express PD-1, we sought to investigate
the phenotype of PD-1+ CD4 effectors infiltrating gliomas as compared to those isolated from
the blood of patients or healthy donors. TIM-3 is a negative regulator of T cell activation and
is also involved in exhaustion, Th1 responses, and response to viral infections [30]. Our previ-
ous work has shown that TIM-3 co-expression with PD-1 marks dysfunctional Tregs in
Fig 2. Administration of IL-2 or of PD-1 blocking antibodies does not recover proliferative function of PD-1+ CD4 effectors in healthy
donors. CFSE labeled CD4 effectors (CD4+CD25—CD127+) stimulated with αCD3/αCD28/αCD2 for 4 days in the presence of either (A) IL-2 (10U/
mL, n = 3) or (B) an anti-PD-1 antibody (10μg/ml, n = 3). Proliferation assessed by CFSE dilution measured by flow cytometry following 4-day
incubation. One representative donor is shown for each. (C) Dot plot summary of 3 independent donors per experimental condition, isotype control
on far-right panel.
https://doi.org/10.1371/journal.pone.0181538.g002
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glioblastoma [22]. Therefore we also sought to characterize TIM-3 expression on CD4 effec-
tors from GBM patients.
PD-1+ and PD-1—CD4 effectors were isolated from fresh tumor resections and matched
peripheral blood from patients with GBM (S6 Table). We observed up-regulation of PD-1 on
the cell surface of CD4 effectors infiltrating gliomas of all WHO tumor grades, with a statisti-
cally significant increase in GBM tumors (Fig 4A, Grade IV) [31].
We also found an increase in the percentage of TIM-3+ CD4 effectors from GBM (WHO
Grade IV) (Fig 4B), as well as an enrichment of PD-1+TIM-3+ CD4 effectors relative to
Fig 3. Transcriptional profiling of PD-1+ CD4 effector cells from healthy donors confirms enrichment in pro-inflammatory and exhaustion
signatures. (A) Gene set enrichment analysis was performed on PD-1+ and PD-1—CD4 effector cells isolated from healthy donors (n = 3). Forest plots
show enrichment of gene sets from each indicated functional category in PD-1+ cells. (B) Top features by rank in PD-1+ or PD-1—subsets are shown, with
selected markers highlighted. (C) Telomere length assessed in ex-vivo sorted CD4 effector (CD4+CD25—CD127+) cells using Telomere PNA Kit for flow
cytometry (Dako) (n = 5). Statistical analyses were performed using paired student’s t-test.
https://doi.org/10.1371/journal.pone.0181538.g003
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peripheral blood (Fig 4C). We found comparable expression of PD-1 on CD4 effector cells
from the blood of patients and healthy donors (Fig 4D). Interestingly, there were no TIM-3+
CD4 effectors in the circulation of healthy controls, and conversely a significant number of cir-
culating CD4 effectors expressing both TIM-3 and PD-1 in patients with GBM (Fig 4D). This
is suggestive of a highly exhausted population of T cells present in the periphery of patients
with GBM.
Overall, we found increased frequencies of PD-1+TIM-3+ CD4 effector cells in blood and
tumors of GBM patients as compared to healthy donors, suggesting a population of tumor-
experienced cells. Previous work has linked PD-1 and TIM-3 expression with T cell exhaustion
and dysfunction in cancer [32], and coupled with our data, suggests that blocking TIM-3 in
conjunction with PD-1 may help mitigate apoptosis and boost effector function of a large frac-
tion of T cells within the GBM tumor environment. Recent work in the context of melanoma
also suggests that expression of PD-1 marks tumor experienced cells [20]. Given that we found
TIM-3+ effectors in glioblastoma patients but not healthy donors, PD-1+TIM-3+ effectors may
also represent a tumor-experienced population of T cells detectable in circulation. We also
found that about half of the patients analyzed showed a more drastic increase in the percentage
of TIM-3+ and PD-1+ effectors. This suggests that study of these cells in a larger cohort of
patients could reveal a method for patient stratification. In sum, our data suggests that further
study of this rare subpopulation of T cells is needed in the context of GBM.
Fig 4. Enrichment of PD-1 and TIM-3 on CD4+ effector cells isolated from GBM tumors. CD4 effector cells were isolated by flow cytometric
sorting from healthy donors and patients with glioblastoma multiforme (GBM). (A) Presence of PD-1+ (A), TIM-3+ (B) and PD-1+TIM-3+ CD4 effectors
(CD4+CD25—CD127+) (C) within glioblastoma tumors (black) and matched blood (white) as a function of tumor grade (n = 6 for II, n = 3 for III, and
n = 9 for IV). Mean + S.D., Two-way ANOVA with Sidak’s multiple comparisons test. (D) Comparison of frequencies of PD-1+, TIM-3+ and PD-1+TIM-
3+ CD4 effectors (CD4+CD25—CD127+) within peripheral blood of healthy controls (n = 7) compared to patients with glioblastoma. Statistical analyses
were performed using student’s t-test.
https://doi.org/10.1371/journal.pone.0181538.g004
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CD4 effector cells isolated from patients with glioblastoma multiforme
have impaired proliferation but retain effector function
To determine the functionality of tumor infiltrating CD4 effector cells as compared to blood,
we isolated CD4 effector cells from GBM tumors and peripheral blood, stimulated them with
αCD3/αCD28/αCD2, and assessed proliferation. Tumor-derived CD4 effectors proliferated
significantly less than those from the peripheral blood (Fig 5A), similar to our observations
from healthy donors. To ascertain whether these CD4 effectors also retained the ability to pro-
duce cytokines, tumor-infiltrating and peripheral blood-derived CD4 effectors were stimulated
with PMA and ionomycin for four hours, the supernatants were collected, and analyzed by
Luminex (S5 Fig). We found that tumor-derived CD4 effector cells retained the ability to pro-
duce inflammatory cytokines, including the pro-inflammatory cytokines IFNγ and GM-CSF.
These data suggest the presence of mixed populations of effector cells capable of secreting
cytokines of the Th1, Th2 or Tr1 lineages as compared to matched CD4 cells from the peripheral
blood. T cells from tumors may secrete high levels of IFNγ to recruit additional CD4 effector cell
help to the CNS in an effort to replenish an exhausted store that is likely unable to perform sup-
portive functions for CD8 T cells, since it has been shown that IFNγ can promote migration of T
cells to the CNS [33]. Previous work has also found that exhaustion and dysfunction can be
induced in CD4 T cells in an IFNγ dependent manner, suggesting that tumor-derived factors
such as secretion of IL-12 from monocytes and macrophages or IFNγ secretion could also con-
tribute to T cell dysfunction in a paracrine manner [34]. Our data indicate that tumor-derived
CD4 effectors are capable of secreting cytokine, including IFNγ; further work at the single-cell
level or profiling of secretion from broader populations of infiltrating immune cells in concert
with tumor-cells is needed to determine potential local drivers of such dysfunction.
CD4 effector cells from blood and tumors of GBM patients are
transcriptionally distinct and tumor-derived PD-1—Teff are enriched in
many gene sets
The expression of PD-1 on T cells isolated from the blood of glioblastoma patients has been
studied previously, however, few have compared molecular profiles to those derived from
Fig 5. CD4 effector cells isolated from GBM tumors are associated with poor proliferation and production of IFNγ and
GM-CSF. (A) Proliferation of peripheral blood or tumor-infiltrating CD4 effectors (CD4+CD25—CD127+) from patients with glioblastoma
multiforme (GBM) (n = 5) as measured by thymidine incorporation. (B) Tumor (black) and peripheral blood (white) derived GBM patient
CD4 effectors (CD4+CD25—CD127+) were sorted and stimulated with PMA (50ng/ml) and Ionomycin (250ng/ml) for 4 hours (n = 4).
Cytokine release measured by Luminex analysis. Statistical analyses were performed using paired student’s t-test.
https://doi.org/10.1371/journal.pone.0181538.g005
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tumors [29,35]. We performed transcriptional profiling to determine if PD-1+ CD4 effector
cells from the blood of GBM patients differed from those found in tumors. PD-1+ and PD-
1—CD4 effectors were isolated from blood and tumors of GBM patients and transcriptionally
profiled by RNA-sequencing. High quality replicates were selected on the basis of sequencing
metrics (S1 Table) and expression of housekeeping genes for subsequent analysis (S2 Table).
Principal components analysis (PCA) revealed that tumor-derived cells, regardless of PD-1 sta-
tus, were transcriptionally distinct from their GBM blood or healthy donor blood derived
counterparts (S6 Fig). The increased spread in tumor samples as compared to blood indicates
a high degree of heterogeneity between patient tumors, even at a bulk level, a finding also
observed in the setting of melanoma [36].
We then performed GSEA in order to compare enriched gene sets from all patients and
healthy donors. We compared the top 100 and bottom 100 ranked genes found in PD-1+ ver-
sus PD-1—T cells from GBM patient blood, tumors, and blood from healthy donors (S7A Fig).
Very few genes were common among all compartments (S7B Fig). This result agrees with pre-
vious transcriptional data showing distinct differences between blood of GBM patients and
healthy donors, and further suggests there are key differences between the blood and tumor
compartments [35]. We found that GITR (tumor necrosis factor receptor superfamily, mem-
ber 18) was one of the shared up-regulated genes in PD-1+ CD4 effectors across compart-
ments, which could suggest a common role in the program of PD-1+ CD4 effector cells. GITR
is a co-stimulatory molecule responsible for maintaining self-tolerance; when blocked it can
induce autoimmunity [37,38]. CD4 effectors thus may up-regulate GITR to prevent anergy
and maintain effector functions in blood and tumors, and future studies should investigate the
specific role of GITR in the context of immune-privileged tumor sites like GBM.
To test the hypothesis that CD4 effectors from tumors are overall more impaired that their
counterparts in blood, regardless of PD-1 status, we performed GSEA using selected replicates
(S2 Table) and compared PD-1+ or PD-1—CD4 effectors from blood as compared to tumors.
We created an enrichment map to visualize the most highly significant gene sets (FDR< 0.01)
(Fig 6A). Many gene sets were enriched in tumor CD4 effectors, regardless of PD-1 status,
including several cell cycle and maintenance gene sets (apoptosis, mRNA processing, and cell
cycle) and immune-related gene sets (cytokine signaling, CTLA4 signaling, and adaptive
immunity). Previous work has established that T cells isolated from GBM are apoptotic [39].
Interestingly, we found enrichment of several metabolic gene sets, including lipid, protein and
TCA cycle genes. Conversely, there were only two groups of genes enriched in blood regardless
of PD-1 status, including one related to steroid hormone metabolism. Surprisingly, we found a
high number of gene sets enriched in tumors in the PD-1—compartment only. These include
immune-related gene sets (co-stimulation, PD-1 signaling, and several chemokines), as well as
a group of gene sets related to carbohydrate and glycerolipid metabolism. Additionally, gene
sets in the PD-1 signaling group also have many connections to other immune groupings,
including carbohydrate and glycerolipid metabolism. The role of metabolism in T cell activa-
tion and function has emerged as a potential therapeutic avenue in addition to checkpoint
blockade in cancer treatment [40]. Although an admittedly small sampling of tumors, our data
indicate that PD-1—CD4 effectors may be overall more metabolically active through the glyco-
lytic and amino acid programs that are necessary to support effector T cell function.
Finally, given that we found enrichment in anergic and exhaustion marker signatures in
healthy donors, apoptotic and inhibitory signaling in GBM patients, but retained ability to
produce cytokines of Th1, Th2, or Tr1 lineages we sought to better determine the relative con-
tribution of these T cell states to each compartment. Using a previously described set of known
exhaustion, Th-specific, memory, and activation gene signatures curated from the literature
(S7 Table), we used GSEA to compare tumor to blood for the PD-1+ and PD-1—T cells from
Functional differences between PD-1+ and PD-1- CD4+ effector t cells in health and glioblastoma
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each compartment (Fig 6B). We found that tumor-derived T cells, regardless of PD-1 status,
were enriched in many gene sets, including Th17, Th1 and several exhaustion as compared to
blood, further supporting the compartment specific differences discussed above.
Taken together, tumor-derived CD4 effectors are transcriptionally different from their
blood-derived counterparts. CD4 effectors from tumors are enriched in many gene sets as
compared to blood, including those that suggest PD-1—CD4 effectors are more metabolically
active and enriched in immune co-stimulation gene sets. Our transcriptional data indicates
that PD-1—CD4 effectors from tumors may be attempting to mount an immune response
while PD-1+ CD4 effectors from tumors may be functionally impaired. Given the large spread
in our transcriptional data set and high-degree of heterogeneity, future work should use sin-
gle-cell approaches to determine the full resolution of T cell states, both transcriptionally and
metabolically, in GBM.
Conclusion
Defining the functional immunological state of PD-1 expressing T cells in the context of health
and cancer is essential to better understanding the efficacy of immune checkpoint blockade.
Previous studies have highlighted the role of PD-1 expression on CD8 and regulatory T cells in
chronic infection and cancer, but few studies have investigated PD-1+ CD4 effector T cells.
Fig 6. Transcriptional profiling of PD-1+ and PD-1—CD4 effectors from tumors and blood of GBM patients reveals unique signatures of
metabolism in the PD-1—compartment and overall exhaustion in tumors. (A) Enrichment map of GSEA results comparing tumors and blood in the
PD-1+ or PD-1—compartment of GBM patients. Gene sets with a FDR < 0.01 are shown as nodes, edges represent gene set overlap, color of the node
represents blood (red) or tumor (blue) and PD-1+ is inside and PD-1—is outside. (B) Heatmap of log(FDR) from GSEA results comparing tumor to blood
within each compartment for curated gene sets described in S7 Table. Significance (FDR < 0.05) is indicated on the color bar.
https://doi.org/10.1371/journal.pone.0181538.g006
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Here, we characterized the role of PD-1 expression on CD4+ T cells from healthy donors and
in the context of GBM.
We found that that PD-1 may identify CD4 effector cells that are irreversibly dysfunctional
as shown by their cytokine production and decreased proliferation that is not rescued by PD-1
blockade. Transcriptionally, PD-1+ CD4 effectors from healthy donors express co-inhibitory
markers and are enriched in several gene sets, including apoptosis, extracellular matrix gene
sets, immune signaling pathways, and activation gene sets. This suggests that PD-1 expression
denotes a population that is functionally distinct, tissue-experienced, activated, and likely
unable to recover from exhaustion. In the context of GBM, we found that tumors have a high
degree of T cell infiltration and CD4 effectors isolated from tumors are able to produce cyto-
kines, including IFNγ as was observed in our data from healthy subjects. Through transcrip-
tional analysis, we found that GITRwas one of the few genes commonly up-regulated in PD-
1+ CD4 effectors in health and GBM. This finding may suggest that CD4 effectors up-regulate
GITR as an attempt to prevent anergy and maintain effector functions in both blood and
tumors (46). Interestingly, we found a number of gene sets enriched in PD-1—CD4 effectors
isolated from tumors of GBM patients. These included immune-related gene sets (co-stimula-
tion, PD-1 signaling, and several chemokines), as well as gene sets related to carbohydrate and
glycerolipid metabolism. The role of metabolism in T cell activation and function has emerged
as a potential therapeutic avenue in addition to checkpoint blockade in cancer treatment (48).
Although a small sampling of tumors, our data indicate that PD-1—CD4 effectors may be over-
all more metabolically active through glycolytic and amino acid programs that are necessary to
support CD4 effector T cell function. Given the large spread in our transcriptional data set and
high-degree of heterogeneity, future work should use single-cell approaches to determine the
full resolution of T cell states, both transcriptionally and metabolically, in GBM.
Finally, we found an increase in the percentage of TIM-3 and PD-1 co-expressing T cells in
tumors of GBM patients and their blood, but not in healthy donors. This may suggest that this
rare population of cells is tumor experienced, and may further indicate that blockade of PD-1
and TIM-3 may be beneficial in the context of GBM immunotherapy. This also suggests that
the immune functions of TIM-3 and PD-1 co-expressing cells should be investigated further in
the context of GBM. In the context of treatment with anti-PD-1 antibodies, our data suggests
that treatment may affect PD-1—CD4 effectors but not PD-1+ CD4 effectors. Clinically, this
suggests that treatment with anti-PD-1 immunotherapy could be greatly enhanced by combin-
ing anti-PD-1 with T cell trafficking agents to promote greater T cell infiltration into the
tumor microenvironment to aid tumor resident PD-1—and PD-1intermediate CD4 effectors per-
form supportive functions.
Materials and methods
Study design and approval
All patients with brain tumors and healthy donors provided samples (human tissue and/or
blood) after informed written consent and approval by the Institutional Review Board at the
Yale School of Medicine. Patients were recruited between 2012 and 2014 on the basis of pre-
sentation with symptoms associated with glioblastoma. Patients with recurrent glioblastoma
were also recruited. Baseline demographic data was recorded for each patient and is summa-
rized in S6 Table. Tumors were histologically characterized by the Pathology Department at
the Yale-New Haven Hospital according to the 2007 WHO classification 59 and immunohisto-
chemical Ki-67 staining performed to measure the proliferative index of each tumor. Immune
monitoring samples were taken from patients as part of the CheckMate 143 clinical trial (Clini-
calTrials.gov Identifier:NCT02017717) of Nivolumab for recurrent GBM.
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Flow cytometry
For cellular isolation and immunophenotyping analyses, flow cytometry was performed using
a BD LSRFortessa for analysis and a BD FACS Aria II for cell sorting. All analysis was carried
out using FlowJo software (Treestar Inc). Cell viability was assessed using Live/Dead Cell Via-
bility Assays (Life technologies). The following anti-human surface and intracellular antibod-
ies and dyes were utilized: anti-CD4 (RPA-T4), anti-CD8 (RPA-T8), anti-CD25 (M-A251),
anti-CD127 (HIL-7R-M21), anti-PD-1 (EH12.1), anti-PDL1 (MIH1) anti-IFNγ(B27), anti-
KI67 (B56), anti-CCR6 (11A9), anti-CXCR3 (IC6), anti-CCR7 (3D12), anti-CXCR5 (RF8B2),
V500 Annexin-V stain (all BD Biosciences); anti-TIM-3 (F38-2E2), anti-CTLA-4 (L3D10),
anti-CD226 (TX25), anti-IL-10 (JES3-9D7) (all from Biolegend), anti-Foxp3 (PCH101), anti-
IL-2 (MQ1-17H12), anti-ICOS (ISA3) (all from eBioscience), anti-LAG-3 (polyclonal goat
IgG, R&D systems), anti-phosphoSer319 FoxO1 (polyclonal rabbit IgG, Bioss).
Tumor infiltrating lymphocyte isolation
For extraction of infiltrating lymphocyte populations, freshly resected tumor specimens were
manually disrupted, digested with collagenase IV (2.5 mg/ml) and DNase I (0.2 mg/ml)
(Worthington Biochemical Corporation) for 1 hour, then passed through a 70mm cell strainer
prior to separation on discontinuous 70–30% Percoll (Sigma Aldrich) gradients. Matched
fresh PBMCs were isolated by Ficoll hypaque gradient centrifugation.
Cell-Trace CFSE proliferation assays
CD4 effector cells (CD4+CD25-CD127+) were isolated via FACS sorting from healthy donors.
To assess proliferative capacity, CD4 effector cells were further sorted based upon PD-1 surface
expression in PD-1+ and PD-1—populations, alongside a total population that was not sorted
by PD-1 expression. CD4 effector cells were stained with CellTrace CFSE (1μM, Life technolo-
gies) to assess proliferation through dilution of the dye. 6 x 103 CD4 effector T cells were cul-
tured for 4 days before assessing for viability and proliferation on a BD LSRFortessa. As
indicated, IL-2 was added at 10U/mL to the culture media. Samples were further analyzed
using FlowJo software.
Blocking antibodies
Human anti-PD-1 (M3, Mouse IgG1) were a generous gift from Dr. Leiping Chen (Yale School
of Medicine, New Haven) and were used at a concentration of 5mg/ml with appropriate iso-
type control antibody.
Telomere length
Telomere length of sorted populations of CD4+CD25—CD127+PD1+ and CD4+CD25—CD127+
PD1—was assessed using the Telomere Peptide Nuclear Antigen kit for flow cytometry (Dako).
Relative telomere length was calculated as the ratio between the telomere signal from each
sorted lymphocyte population and the 1301 control cell line (Sigma Aldrich).
Thymidine incorporation
To assess growth potential of lymphocytes, CD4 effector cells (CD4+CD25-CD127+) were iso-
lated via FACS sorting from blood and tumors of patients with GBM. Cells were cultured in
the presence of 2 Treg Inspector Beads (anti-CD2/anti-CD3/anti-CD28) (Miltenyi) per cell.
No fewer than 2000 cells were cultured. After 72 hours cells were pulsed with 0.5uCi 3H
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Thymidine and harvested 18 hours later. 3H-thymidine incorporation was measured using a
micro beta counter.
Luminex
Multiplex assays for cytokine secretion were performed on cell culture supernatants after stim-
ulation with PMA (50ng/ml) and Ionomycin (250ng/ml) using Milliplex Human Cytokine/
Chemokine Magnetic Bead Panel (Millipore) and analyzed as described in supplementary
materials.
Luminex data analysis
Data were analyzed using custom MATLAB scripts. Briefly, data were z-score normalized and
included for analysis based on pearson correlation scores. Data were then hierarchically
clustered.
RNA-sequencing
T cells from healthy controls and GBM patients were sorted into RNA lysis buffer for RNA
sequencing as described previously [41]. Briefly, RNA was extracted using the NucleoSpin
RNA XS Kit (Macherey-Nagel) according to the manufacturers instructions. cDNA synthesis
and amplification were performed using SMARTer Ultra Low Input RNA for Illumina
Sequencing High Volume Kit (Clontech) according to the manufacturers instructions, with
the following for LD amplification: [98˚C for 10s, 65˚C for 30s, 68˚C for 3min]x18, 72˚C for
10min. cDNA was normalized post quantification using Picogreen (Invitrogen) to an input of
0.5ng total for preparing sequencing libraries. Paired-end sequencing libraries were prepared
using the Nextera XT DNA sample Prep Kit (Illumina) according to the manufacturers
instructions. Libraries were pooled in an equimolar ratio and sequenced on a HiSeq 2500
sequencer with 200 cycles per lane (Illumina). In depth analysis methods are discussed in the
Supplementary Information. All sequencing data are available through DbGaP (#18460).
Reads were mapped against UCSC’s known genes annotation of the hg19 human genome
assembly using RSEM v 1.2.15 and bowtie 1.0.1 (parameters -p 4—output-genome-bam—
calc-ci—paired-end—bowtie-chunkmbs 1024).[42] Posterior estimates of counts per genes
were retrieved for processing in the R statistical environment v. 3.1.1, using the DESeq pack-
age.[43] After normalization (estimateSizeFactors) and variance estimates across all samples
using the estimateDispersions function similar to its original implementation (sample-blind
estimate and fit-only sharing mode), differential expression was performed either pairwise
between every combinations of sample labels (nbinomTest) or by building a GLM model to
test every condition independently (fitNbinomGLMs). P-values were adjusted using the Benja-
min-Hochberg procedure (p.adjust).
Quality control was performed on forward and reverse fastq files from each sample using
custom python scripts. QC metrics used were number and percentage of mapped reads, reads
mapping to exonic, intronic, CDS, 5’ and 3’ untranslated regions, intergenic regions and dif-
ferent classes of non-coding RNAs. Additional metrics reflecting the mRNA enrichment were
derived from exonic/intronic read density ratios, and biases in RNA integrity were detected
using the 5’/3’ ratios. Samples kept for down stream analysis are shown in S1 Table. The
log2FPKM values for mapped transcripts in each sample were used to create the input.gct file
for Gene Set Enrichment Analysis (GSEA) (v17.0). GSEA (classic scoring scheme, signal to
noise ranking, 15 gene set size minimum, 1000 permutations) was performed using C2CP
gene sets and custom gene sets curated from the literature. Data were further analyzed using
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DAVID for functional classification. GeneE data visualization tool (http://www.broadinstitute.
org/cancer/software/GENE-E/index.html) was used to create heatmaps of selected genes.
Enrichment maps of GSEA data were created using Enrichment Map in Cytoscape (v3.3.0)
with a p-value cutoff of 0.005, FDR Q-value cutoff of 0.01, and an overlap coefficient of 0.5,
and a combined constant of 0.5. To investigate connections between interesting gene sets, we
highlighted connections from carbohydrate signaling (unique to PD-1—tumors), PD-1 signal-
ing (unique to PD-1—tumors), and apoptosis (common to tumors regardless of PD-1 status).
Statistics
Statistical analysis was carried out using GraphPad Prism (GraphPad Inc). Paired and
unpaired two tailed students t tests were used when appropriate. P<0.05 was considered statis-
tically significant.
Supporting information
S1 Fig. Gating strategy for the isolation of PD-1+ CD4 effector cells. Representative plot
showing gates for CD4 effectors CD4+CD25—CD127+) and (Tregs (CD4+CD25hiCD127lo)
among total CD4+ cells based on isotype control and on PD-1 stain.
(PDF)
S2 Fig. Proliferative impairment of PD-1+ CD4 effectors independent of CD45RO expres-
sion. CFSE labeled CD4 effectors (CD4+CD25—CD127+) stimulated with αCD3/αCD28/
αCD2 for 4 days. Proliferation assessed by CFSE dilution measured by flow cytometry. Repre-
sentative plots displayed from 1 of 5 independent experiments.
(PDF)
S3 Fig. Differential expression analysis of PD-1+ and PD-1—CD4 effectors from healthy
donors. (a) Volcano plot of differentially expressed genes with select genes with padj
values> 0.05 highlighted in pink and select genes annotated. (b) Forest plot of p-values of top
GO enrichment analysis terms of genes up in PD-1+ CD4 effectors. Data from 3 healthy
donors.
(PDF)
S4 Fig. Characterization of surface markers on PD-1+ and PD-1− CD4 effectors. Expression of
selected cell markers within PD-1+ and PD-1− CD4 effector (CD4+CD25—CD127+) populations
(n = 25 total). The percent of cells expressing several markers were significantly different, includ-
ing CD27 (p = 0.0006), CD45RA (p = 0.0037), CD45RO (p = 0.0032), CD57 (p = 0.0004), CD62L
(p = 0.0009), CCR6 (p = 0.0059), CCR7 (p = 0.0021), ICOS (p = 0.0101), PDL1 (p = 0.0061), and
LAG3 (p = 0.0008) were all significantly different, with p values indicated by paired students
t test.
(PDF)
S5 Fig. Analysis of Luminex data from blood and tumor derived CD4 effectors from GBM
patients. (a) Box plots of z-score normalized luminex measurements for each patient. (b) Cor-
relation matrix of all data from tumors and blood.
(PDF)
S6 Fig. Principal components analysis (PCA) of transcriptional data from all patients. (a)
Principal components analysis of transcriptional data (log2(FPKM+1)>0.01) from all samples
analyzed. Data points are labeled from glioblastoma (GBM) blood, tumor, or healthy blood.
(b) Percent variance accounted for in each component.
(PDF)
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S7 Fig. Comparison of GSEA results from healthy donors, GBM tumors and GBM blood.
(a) Heatmaps of the top 50 features identified by GSEA are shown for all samples analyzed
from PD-1+ and PD-1—CD4 effectors. (b) Venn diagram comparisons of features enriched in
PD-1+ (top) or PD-1—(bottom) CD4 effectors. Members of several overlaps are annotated.
(PDF)
S1 Table. Transcriptional data and sequencing metrics.
(PDF)
S2 Table. Selected housekeeping genes used for quality control of transcriptional data.
(PDF)
S3 Table. Differentially expressed genes for PD-1+ versus PD-1—CD4 effectors from
healthy donors.
(PDF)
S4 Table. DAVID gene classification for PD-1+ healthy donors. Enrichment scores are
shown for each group.
(PDF)
S5 Table. Gene set enrichment results for PD1 positive and negative Teff from healthy
donors (FDR<0.05).
(PDF)
S6 Table. Data for patients used in this study.
(PDF)
S7 Table. Curated exhaustion and T cell specific gene signatures from the literature.
(PDF)
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